Novo Nordisk A/S (NOVO-B)の価格はいくらですか

Novo Nordisk A/S (NOVO-B)の価格は$43.92です

Novo Nordisk A/S (NOVO-B)の時価総額は何ですか

Novo Nordisk A/S (NOVO-B)の時価総額は$195.10Bです

Novo Nordisk A/S (NOVO-B) の収益

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

年	収益	変化
提供された日付のデータは十分ではありません。

年

収益

変化

提供された日付のデータは十分ではありません。

企業	収益	収益の差	国
Eli Lilly and Company LLY.US	$79.67B	64.19%	US
Johnson & Johnson JNJ.US	$97.93B	101.83%	US
AbbVie Inc. ABBV.US	$64.39B	32.70%	US
Roche Holding AG RO.SW	$77.52B	59.77%	CH
Merck & Co., Inc. MRK.US	$66.40B	36.85%	US

企業

収益

収益の差

国